Telmisartan acts through the modulation of ACE-2/ANG 1-7/mas receptor in rats with dilated cardiomyopathy induced by experimental autoimmune myocarditis

Vijayakumar Sukumaran, Punniyakoti T. Veeraveedu, Narasimman Gurusamy, Arun Lakshmanan, Ken'Ichi Yamaguchi, Meilei Ma, Kenji Suzuki, Makoto Kodama, Kenichi Watanabe

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Aim: Recent findings have suggested that a therapeutic approach to amplify or stimulate the angiotensin-converting enzyme-2 [ACE-2]-angiotensin 1-7 [ANG 1-7] mas axis could provide protection against the development of cardiovascular diseases. We investigated the cardioprotective effects of telmisartan in rats with dilated cardiomyopathy [DCM] after experimental autoimmune myocarditis [EAM]. Main methods: DCM was elicited in Lewis rats by immunization with cardiac myosin, and twenty-eight days after immunization, the surviving Lewis rats were divided into two groups and treated with either telmisartan (10 mg/kg/day) or vehicle. Key findings: Telmisartan treatment effectively suppressed myocardial protein and mRNA expressions of inflammatory markers [CD68, iNOS, NF-kB, interleukin-1β, interferon-γ, monocyte chemotactic protein-1] in comparison to vehicle-treated rats. In contrast, myocardial protein levels of ACE-2 and ANG 1-7 mas receptor were upregulated in the telmisartan-treated group compared with vehicle-treated rats. Telmisartan treatment significantly reduced fibrosis and hypertrophy and their marker molecules [OPN, CTGF, TGF-β1 and collagens I and III and atrial natriuretic peptide and GATA-4, respectively] compared with those of vehicle-treated rats. In addition, telmisartan treatment significantly lowered the protein expressions of NADPH oxidase subunits p47phox, p67phox, and superoxide production when compared with vehicle-treated rats. Telmisartan treatment significantly decreased the expression levels of mitogen-activated protein kinase (MAPK) signaling molecules than with those of vehicle-treated rats. Also, telmisartan treatment significantly improved LV systolic and diastolic function. Significance: These results indicate that telmisartan treatment significantly improved LV function and ameliorated the progression of cardiac remodeling through the modulation of ACE-2/ANG 1-7/Mas receptor axis in rats with DCM after EAM.

Original languageEnglish
Pages (from-to)289-300
Number of pages12
JournalLife Sciences
Volume90
Issue number7-8
DOIs
Publication statusPublished - 13 Feb 2012
Externally publishedYes

Fingerprint

Myocarditis
Dilated Cardiomyopathy
Rats
Modulation
Immunization
Therapeutics
Cardiac Myosins
angiotensin converting enzyme 2
angiotensin I (1-7)
telmisartan
Proteins
Molecules
NF-kappa B
Chemokine CCL2
NADPH Oxidase
Atrial Natriuretic Factor
Mitogen-Activated Protein Kinases
Interleukin-1
Superoxides
Interferons

Keywords

  • Angiotensin 1-7
  • Angiotensin converting enzyme-2
  • Dilated cardiomyopathy
  • Inflammation
  • Oxidative stress
  • Telmisartan

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Telmisartan acts through the modulation of ACE-2/ANG 1-7/mas receptor in rats with dilated cardiomyopathy induced by experimental autoimmune myocarditis. / Sukumaran, Vijayakumar; Veeraveedu, Punniyakoti T.; Gurusamy, Narasimman; Lakshmanan, Arun; Yamaguchi, Ken'Ichi; Ma, Meilei; Suzuki, Kenji; Kodama, Makoto; Watanabe, Kenichi.

In: Life Sciences, Vol. 90, No. 7-8, 13.02.2012, p. 289-300.

Research output: Contribution to journalArticle

Sukumaran, Vijayakumar ; Veeraveedu, Punniyakoti T. ; Gurusamy, Narasimman ; Lakshmanan, Arun ; Yamaguchi, Ken'Ichi ; Ma, Meilei ; Suzuki, Kenji ; Kodama, Makoto ; Watanabe, Kenichi. / Telmisartan acts through the modulation of ACE-2/ANG 1-7/mas receptor in rats with dilated cardiomyopathy induced by experimental autoimmune myocarditis. In: Life Sciences. 2012 ; Vol. 90, No. 7-8. pp. 289-300.
@article{6fda40e3a73a4d28879ff4ea578d7442,
title = "Telmisartan acts through the modulation of ACE-2/ANG 1-7/mas receptor in rats with dilated cardiomyopathy induced by experimental autoimmune myocarditis",
abstract = "Aim: Recent findings have suggested that a therapeutic approach to amplify or stimulate the angiotensin-converting enzyme-2 [ACE-2]-angiotensin 1-7 [ANG 1-7] mas axis could provide protection against the development of cardiovascular diseases. We investigated the cardioprotective effects of telmisartan in rats with dilated cardiomyopathy [DCM] after experimental autoimmune myocarditis [EAM]. Main methods: DCM was elicited in Lewis rats by immunization with cardiac myosin, and twenty-eight days after immunization, the surviving Lewis rats were divided into two groups and treated with either telmisartan (10 mg/kg/day) or vehicle. Key findings: Telmisartan treatment effectively suppressed myocardial protein and mRNA expressions of inflammatory markers [CD68, iNOS, NF-kB, interleukin-1β, interferon-γ, monocyte chemotactic protein-1] in comparison to vehicle-treated rats. In contrast, myocardial protein levels of ACE-2 and ANG 1-7 mas receptor were upregulated in the telmisartan-treated group compared with vehicle-treated rats. Telmisartan treatment significantly reduced fibrosis and hypertrophy and their marker molecules [OPN, CTGF, TGF-β1 and collagens I and III and atrial natriuretic peptide and GATA-4, respectively] compared with those of vehicle-treated rats. In addition, telmisartan treatment significantly lowered the protein expressions of NADPH oxidase subunits p47phox, p67phox, and superoxide production when compared with vehicle-treated rats. Telmisartan treatment significantly decreased the expression levels of mitogen-activated protein kinase (MAPK) signaling molecules than with those of vehicle-treated rats. Also, telmisartan treatment significantly improved LV systolic and diastolic function. Significance: These results indicate that telmisartan treatment significantly improved LV function and ameliorated the progression of cardiac remodeling through the modulation of ACE-2/ANG 1-7/Mas receptor axis in rats with DCM after EAM.",
keywords = "Angiotensin 1-7, Angiotensin converting enzyme-2, Dilated cardiomyopathy, Inflammation, Oxidative stress, Telmisartan",
author = "Vijayakumar Sukumaran and Veeraveedu, {Punniyakoti T.} and Narasimman Gurusamy and Arun Lakshmanan and Ken'Ichi Yamaguchi and Meilei Ma and Kenji Suzuki and Makoto Kodama and Kenichi Watanabe",
year = "2012",
month = "2",
day = "13",
doi = "10.1016/j.lfs.2011.11.018",
language = "English",
volume = "90",
pages = "289--300",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "7-8",

}

TY - JOUR

T1 - Telmisartan acts through the modulation of ACE-2/ANG 1-7/mas receptor in rats with dilated cardiomyopathy induced by experimental autoimmune myocarditis

AU - Sukumaran, Vijayakumar

AU - Veeraveedu, Punniyakoti T.

AU - Gurusamy, Narasimman

AU - Lakshmanan, Arun

AU - Yamaguchi, Ken'Ichi

AU - Ma, Meilei

AU - Suzuki, Kenji

AU - Kodama, Makoto

AU - Watanabe, Kenichi

PY - 2012/2/13

Y1 - 2012/2/13

N2 - Aim: Recent findings have suggested that a therapeutic approach to amplify or stimulate the angiotensin-converting enzyme-2 [ACE-2]-angiotensin 1-7 [ANG 1-7] mas axis could provide protection against the development of cardiovascular diseases. We investigated the cardioprotective effects of telmisartan in rats with dilated cardiomyopathy [DCM] after experimental autoimmune myocarditis [EAM]. Main methods: DCM was elicited in Lewis rats by immunization with cardiac myosin, and twenty-eight days after immunization, the surviving Lewis rats were divided into two groups and treated with either telmisartan (10 mg/kg/day) or vehicle. Key findings: Telmisartan treatment effectively suppressed myocardial protein and mRNA expressions of inflammatory markers [CD68, iNOS, NF-kB, interleukin-1β, interferon-γ, monocyte chemotactic protein-1] in comparison to vehicle-treated rats. In contrast, myocardial protein levels of ACE-2 and ANG 1-7 mas receptor were upregulated in the telmisartan-treated group compared with vehicle-treated rats. Telmisartan treatment significantly reduced fibrosis and hypertrophy and their marker molecules [OPN, CTGF, TGF-β1 and collagens I and III and atrial natriuretic peptide and GATA-4, respectively] compared with those of vehicle-treated rats. In addition, telmisartan treatment significantly lowered the protein expressions of NADPH oxidase subunits p47phox, p67phox, and superoxide production when compared with vehicle-treated rats. Telmisartan treatment significantly decreased the expression levels of mitogen-activated protein kinase (MAPK) signaling molecules than with those of vehicle-treated rats. Also, telmisartan treatment significantly improved LV systolic and diastolic function. Significance: These results indicate that telmisartan treatment significantly improved LV function and ameliorated the progression of cardiac remodeling through the modulation of ACE-2/ANG 1-7/Mas receptor axis in rats with DCM after EAM.

AB - Aim: Recent findings have suggested that a therapeutic approach to amplify or stimulate the angiotensin-converting enzyme-2 [ACE-2]-angiotensin 1-7 [ANG 1-7] mas axis could provide protection against the development of cardiovascular diseases. We investigated the cardioprotective effects of telmisartan in rats with dilated cardiomyopathy [DCM] after experimental autoimmune myocarditis [EAM]. Main methods: DCM was elicited in Lewis rats by immunization with cardiac myosin, and twenty-eight days after immunization, the surviving Lewis rats were divided into two groups and treated with either telmisartan (10 mg/kg/day) or vehicle. Key findings: Telmisartan treatment effectively suppressed myocardial protein and mRNA expressions of inflammatory markers [CD68, iNOS, NF-kB, interleukin-1β, interferon-γ, monocyte chemotactic protein-1] in comparison to vehicle-treated rats. In contrast, myocardial protein levels of ACE-2 and ANG 1-7 mas receptor were upregulated in the telmisartan-treated group compared with vehicle-treated rats. Telmisartan treatment significantly reduced fibrosis and hypertrophy and their marker molecules [OPN, CTGF, TGF-β1 and collagens I and III and atrial natriuretic peptide and GATA-4, respectively] compared with those of vehicle-treated rats. In addition, telmisartan treatment significantly lowered the protein expressions of NADPH oxidase subunits p47phox, p67phox, and superoxide production when compared with vehicle-treated rats. Telmisartan treatment significantly decreased the expression levels of mitogen-activated protein kinase (MAPK) signaling molecules than with those of vehicle-treated rats. Also, telmisartan treatment significantly improved LV systolic and diastolic function. Significance: These results indicate that telmisartan treatment significantly improved LV function and ameliorated the progression of cardiac remodeling through the modulation of ACE-2/ANG 1-7/Mas receptor axis in rats with DCM after EAM.

KW - Angiotensin 1-7

KW - Angiotensin converting enzyme-2

KW - Dilated cardiomyopathy

KW - Inflammation

KW - Oxidative stress

KW - Telmisartan

UR - http://www.scopus.com/inward/record.url?scp=84862817448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862817448&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2011.11.018

DO - 10.1016/j.lfs.2011.11.018

M3 - Article

VL - 90

SP - 289

EP - 300

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 7-8

ER -